STOCK TITAN

LB Pharmaceuticals (LBRX) Stock News, Sep-Nov 2025

LBRX NASDAQ

LB Pharmaceuticals Inc develops novel therapies for neuropsychiatric diseases, led by LB-102, an oral investigational small molecule and benzamide antipsychotic candidate for schizophrenia, bipolar depression and adjunctive major depressive disorder. Company news frequently centers on LB-102 clinical data, peer-reviewed publications, medical-conference presentations and trial-program updates across schizophrenia and mood-disorder indications.

Other recurring updates include financial results, capital-raising activity, board and executive appointments, Nasdaq inducement grants and healthcare-conference participation. These announcements frame the company's single-segment biopharmaceutical model around clinical development, financing needs and governance as it advances LB-102.

Rhea-AI Summary

LB Pharmaceuticals (Nasdaq: LBRX) announced that CEO Heather Turner will present at the Piper Sandler 37th Annual Healthcare Conference in New York on Wednesday, December 3, 2025 at 9:30 a.m. ET.

A live webcast will be available on the company’s Investors > Events page and a replay will be archived there.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.28%
Tags
none
-
Rhea-AI Summary

LB Pharmaceuticals (NASDAQ: LBRX) announced an inducement equity award to James Rawls upon his hiring as Senior Vice President of Regulatory Affairs.

On November 10, 2025 the company granted Mr. Rawls an option to purchase 90,000 shares of common stock under the Nasdaq Listing Rule 5635(c)(4) inducement exception. The option has a 10-year term, an exercise price of $14.61 per share (the closing price on the grant date), and vests over 4 years with 25% vesting on the first anniversary and the remainder vesting monthly at 1/48th, subject to continued service.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.19%
Tags
none
-
Rhea-AI Summary

LB Pharmaceuticals (Nasdaq: LBRX) announced on November 12, 2025 the appointment of Kaya Pai Panandiker as Chief Commercial Officer.

Ms. Pai Panandiker brings more than 20 years of global biopharmaceutical commercial experience, including neuroscience commercialization, prior roles as Chief Commercial Officer at Neumora Therapeutics, Head of Commercial at Cerevel Therapeutics (acquired by AbbVie in 2024), and General Manager, Neuroscience at Lundbeck U.S.

The company said her experience launching and scaling global neuroscience brands will support advancement of LB-102 toward registration and commercialization.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.63%
Tags
none
Rhea-AI Summary

LB Pharmaceuticals (Nasdaq: LBRX) announced that Heather Turner, Chief Executive Officer, will present at the Stifel 2025 Healthcare Conference in New York on Thursday, November 13, 2025 at 9:20 a.m. ET.

A live webcast will be available on the company’s Investors > Events page at https://ir.lbpharma.us/investors/events/, and a replay will be archived there after the presentation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.03%
Tags
none
-
Rhea-AI Summary

LB Pharmaceuticals (Nasdaq: LBRX) reported 3Q 2025 results and corporate updates on Nov 6, 2025. The company completed an upsized IPO of 21,850,000 shares at $15.00 raising $327.8M gross and held $314.5M cash, projected to fund operations into Q2 2028. LB-102 Phase 2 NOVA1 data showed dose-dependent cognitive effect sizes vs placebo of 0.26 (50 mg), 0.41 (75 mg) and 0.66 (100 mg). The company plans a Phase 3 acute schizophrenia trial (sample size increased from ~400 to ~460) starting in Q1 2026 with topline in H2 2027, and a potentially registrational Phase 2 bipolar depression trial starting Q1 2026 with topline in Q1 2028.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.26%
Tags
-
Rhea-AI Summary

LB Pharmaceuticals (Nasdaq: LBRX) appointed James Rawls, Pharm.D. as Senior Vice President of Regulatory Affairs on October 14, 2025.

Dr. Rawls brings 25+ years of regulatory leadership, with experience at Novartis, Sunovion, Sumitomo Pharma America, and Boston Biodevelopment, and has contributed to multiple global regulatory filings and product approvals. The company said his expertise will support advancing LB-102 into a Phase 3 schizophrenia trial and a Phase 2 bipolar depression trial planned for 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.80%
Tags
none
Rhea-AI Summary

LB Pharmaceuticals (Nasdaq: LBRX) will present three posters at the 38th ECNP Congress (Amsterdam, Oct 11-14, 2025) reporting analyses from the Phase 2 NOVA1 trial of LB-102 in acute schizophrenia.

A post-hoc cognitive analysis showed dose-dependent, statistically significant effect sizes versus placebo at 4 weeks: 0.26 (p=0.0476) at 50 mg, 0.41 (p=0.0027) at 75 mg and 0.66 (p=0.0018) at 100 mg in a completer population. Additional posters cover primary NOVA1 efficacy/safety results and a post-hoc analysis on negative symptoms. Posters go live on the company website on Oct 11, 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.60%
Tags
conferences
-
Rhea-AI Summary

LB Pharmaceuticals (NASDAQ:LBRX) has strengthened its Board of Directors with two strategic appointments following its IPO on September 10, 2025. The company has added William Kane, current President and CEO of Uniquity Bio with extensive commercialization experience, and Rekha Hemrajani, who brings significant financial and operational expertise.

These appointments come at a crucial time as LB Pharmaceuticals prepares to advance its lead product candidate, LB-102, into Phase 3 trials for acute schizophrenia and Phase 2 trials for bipolar depression in early 2026. LB-102 is positioned to potentially become the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.33%
Tags
management
-
Rhea-AI Summary

LB Pharmaceuticals (NASDAQ:LBRX) has announced the pricing of its upsized initial public offering, offering 19,000,000 shares of common stock at $15.00 per share. The company expects to raise $285.0 million in gross proceeds before deducting underwriting costs and other expenses.

The IPO includes a 30-day option for underwriters to purchase up to 2,850,000 additional shares. Trading is set to commence on the Nasdaq Global Market on September 11, 2025, under the ticker symbol "LBRX". The offering is expected to close on September 12, 2025, with Leerink Partners, Piper Sandler, and Stifel serving as joint bookrunning managers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags

FAQ

What is the current stock price of LB Pharmaceuticals (LBRX)?

LB Pharmaceuticals (LBRX) last closed at $38.85.

What is the market cap of LB Pharmaceuticals (LBRX)?

The market cap of LB Pharmaceuticals (LBRX) is approximately $1.3B.